Table 3.
Results of adherence analysis
| Adherence (period: first 12 months after treatment initiation) | UK: CPRD | GER: AOK PLUS | ||||
|---|---|---|---|---|---|---|
| T2DM-prevalent patients having started a therapy with GLP-1 receptor agonists | T2DM-prevalent patients having started a OD therapy with GLP-1 receptor agonists (no switching to BID/once-weekly) | T2DM-prevalent patients having started a BID therapy with GLP-1 receptor agonists (no switching to OD/once-weekly) | T2DM-prevalent patients having started a therapy with GLP-1 receptor agonists | T2DM-prevalent patients having started a OD therapy with GLP-1 receptor agonists (no switching to BID/once-weekly) | T2DM-prevalent patients having started a BID therapy with GLP-1 receptor agonists (no switching to OD/once-weekly) | |
| 1. Overall MPR for 12 months observational period since therapy starta | ||||||
| N | 1905 | 1083 | 545 | 1627 | 1180 | 295 |
| Mean MPR in % (SD) | 76.0 (29.0) | 76.5 (28.2) | 73.2 (31.7) | 73.9 (29.5) | 74.1 (29.1) | 69.7 (32.1) |
| Patients affected by NA: MPR <80%, (%) | 711 (37.3%) | 391 (36.1%) | 226 (41.5%) | 685 (42.1%) | 488 (41.4%) | 148 (50.2%) |
| 2. Adherence between first and last observed prescription during therapy persistenceb | ||||||
| N | 1744 | 998 | 484 | 1349 | 975 | 234 |
| Mean observational period in days (SD) | 288.6 (96.5) | 295.1 (90.1) | 272.2 (109.0) | 253.6 (98.6) | 255.4 (97.7) | 233.9 (104.9) |
| Mean MPR in % (SD) | 88.6 (14.9) | 88.2 (15.0) | 89.3 (15.6) | 89.7 (15.0) | 90.0 (14.7) | 89.4 (15.9) |
| Patients affected by NA: MPR <70%, (%) | 222 (12.7%) | 133 (13.3%) | 60 (12.4%) | 164 (12.2%) | 115 (11.8%) | 33 (14.1%) |
| Patients affected by NA: MPR <80%, (%) | 353 (20.2%) | 200 (20.0%) | 99 (20.5%) | 269 (19.9%) | 187 (19.2%) | 51 (21.8%) |
| Patients affected by NA: MPR <90%, (%) | 635 (36.4%) | 375 (37.6%) | 161 (33.3%) | 443 (32.8%) | 315 (32.3%) | 77 (32.9%) |
The table lists results of adherence analysis
UK United Kingdom, CPRD Clinical Practice Research Datalink, GER Germany, AOK Allgemeine Ortskrankenkasse, T2DM type 2 diabetes mellitus, GLP-1 glucagon-like peptide-1, OD once daily, BID twice daily, NP non-persistence, MPR medication possession ratio, SD standard deviation, NA non-adherence
aMPR calculation was done for a fixed period of 360 days (or, in case of death within this period, for the time until the date of death)
bMPR calculation for the time between the first and last prescription during persistent treatment periods